Learn about the legal battle between Bristol Myers Squibb and the HHS over the 340B drug pricing program, as other drugmakers join in with rebate plans.
Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.
Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback